Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background: About one-third of patients with depression fail to achieve remission despite treatment with multiple antidepressants and are considered to have treatment-resistant depression. Methods: This Phase 3, double-blind, multicenter study enrolled adults with moderate-to-severe depression and nonresponse to ≥2 antidepressants in the current depression episode. Eligible patients (N = 346) were randomized (1:1:1) to twice-weekly nasal spray treatment (esketamine [56 or 84 mg] or placebo) plus a newly initiated, open-label, oral antidepressant taken daily for 4 weeks. The primary efficacy endpoint was change from baseline to day 28 in the Montgomery-Asberg Depression Rating Scale total score, performed by blinded, remote raters. Based on the predefined statistical testing sequence, esketamine 84 mg/antidepressant had to be significant for esketamine 56 mg/antidepressant to be formally tested. Results: Statistical significance was not achieved with esketamine 84 mg/antidepressant compared with antidepressant/placebo (least squares [LS] means difference [95% CI]: –3.2 [–6.88, 0.45]; 2-sided P value = .088). Although esketamine 56 mg/antidepressant could not be formally tested, the LS means difference was –4.1 [–7.67, –0.49] (nominal 2-sided P value = .027). The most common (>20%) adverse events reported for esketamine/antidepressant were nausea, dissociation, dizziness, vertigo, and headache. Conclusions: Statistical significance was not achieved for the primary endpoint; nevertheless, the treatment effect (Montgomery-Asberg Depression Rating Scale) for both esketamine/antidepressant groups exceeded what has been considered clinically meaningful for approved antidepressants vs placebo. Safety was similar between esketamine/antidepressant groups and no new dose-related safety concerns were identified. This study provides supportive evidence for the safety and efficacy of esketamine nasal spray as a new, rapid-acting antidepressant for patients with treatment-resistant depression. Trial Registration: ClinicalTrials.gov identifier: NCT02417064
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2. Least squares mean change (±SE) in Montgomery-Asberg Depression Rating Scale (MADRS) total score over time in double-blind phase (observed cases mixed model for repeated measures [MMRM]). LS, least squares; SE, standard error. LS mean and SE were based on MMRM with change from baseline as the response variable and the fixed effect model terms for treatment (esketamine 56 mg/antidepressant, esketamine 84 mg/antidepressant, antidepressant/placebo), day, region, class of oral antidepressant, and treatment-by-day, and baseline value as a covariate. Results are not adjusted for multiple comparisons or sample size reestimation. Negative change in score indicates improvement.](https://figures.cochat.ai/paper-figures/2c4f045dfb03494db68f2585854e303a/efficacy-and-safety-of-fixed-dose-esketamine-nasal-spray-combined-with-a-new-figure-2.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Fedgchin’s group conducted an analogous study, which did not support adjunctive esketamine’s AD efficacy for TRD [111].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [111]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials found that esketamine, in combination with an oral antidepressant, rapidly reduced suicidal thoughts compared to placebo in adults with TRD who were at imminent risk for suicide [65,88,89].”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [88]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In one of those (NCT02417064 [9]), statistical significance should not have been tested for the 56 mg treatment group due to the hierarchical analysis and the absence of a significant difference in the 84 mg group tested first.”
From Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials (2025) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, when reviewing the major esketamine trials, significantly increased rates of somnolence versus placebo have been reported, especially in relapse-prevention studies,74,152 but this has not been seen consistently.153”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [152]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because this was statistically tested when it should not have been, it introduced some spin into the published report [9], despite the numerical results being deemed reproducible.”
From Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials (2025) · cites this paper as [9]
Experimental — accuracy not yet measured
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.10.1092 · Cited by 31,765
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Diagnostic and Statistical Manual of Mental Disorders(DSM)
(2008) · Encyclopedia of Counseling · doi:10.4135/9781412963978.n182 · Cited by 10,830
Spitzer, R. L. (1999) · JAMA · doi:10.1001/jama.282.18.1737 · Cited by 9,802
(1976) · Medical Entomology and Zoology · Cited by 8,899
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“In patients who respond to biogenic amine antidepressants, the time to onset of effect is typically 3 to 7 weeks, during which time patients remain symptomatic and at risk of self-harm (Rush et al., 2006).”
BackgroundSelf-citationDiagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · cited 5×
“About one-third of patients with MDD fail to achieve remission despite treatment with multiple biogenic amine (e.g., serotonin, norepinephrine) antidepressants and hence have treatment-resistant depression (TRD) (Fava, 2003).”
BackgroundMethodInfluentialSelf-citationKennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Self-citationPosner, K., Oquendo, M. A., Gould, M., Stanley, B., & Davies, M. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1035 · Cited by 1,025
Cited by
Items 501–600 of 679
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.087
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.040
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.076
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0120
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.010
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0148
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.069
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0149
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.060
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0144
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.072
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.050
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.053
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.033
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.059
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.056
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.096
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0132
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.099
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.025
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.022
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.030
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.023
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0143
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.068
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.041
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.092
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.004
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0134
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.067
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0152
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.039
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.047
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.065
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.084
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.002
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.057
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0109
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0125
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.013
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.003
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.079
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.091
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.042
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.006
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.038
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0139
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.005
Optimal unplanned design modification in adaptive two‐stage trials
Pilz, M., Herrmann, C., Rauch, G., & Kieser, M. (2022) · Pharmaceutical Statistics · doi:10.1002/pst.2228
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.100
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.110
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.119
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.146
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.113
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.101
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.115
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.126
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.111
Index by Use: Commonly Prescribed For (bold for FDA approved)
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.155
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.121
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.114
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.141
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.118
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.116
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.151
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.104
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.136
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.137
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.102
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.127
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.140
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.117
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.133
Tao, Y., Xu, H., & Huang, X. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.10.013
New Pharmacological Therapeutic Approaches for Depressive Disorders: A Systematic Review
de Aquino, T. L., Libório, J. R., Bezerra, A. L. M. S., Cavalcante, G. M. E., Duarte, D. F. B., Martin, A. L. D. A. R., de Paula, J. D. A., & Neto, M. L. R. (2021) · Journal of Anxiety & Depression · doi:10.46527/2582-3264.138
Influence of ketamine in adults with major depression and impact at the cognitive level
Gualda, L. M. G., Garcia, M., Povedano, R. S., Lozano, M. J. M., Rodenas, P. R., Pérez-Romero, M. L., Fernández-Sotos, P., & Dies, M. A. (2022) · Neuroscience Applied · doi:10.1016/j.nsa.2022.100502
Therapeutic Use of Ketamine in Psychiatric Disorders
Jones, J., Morgan, C. J. A., & Malcolm, R. J. (2023) · Frontiers research topics · doi:10.3389/978-2-8325-1050-6
Methods and applications in psychology for clinical settings
(2023) · Frontiers research topics · doi:10.3389/978-2-8325-2850-1
Sex Differences in the Antidepressant Effects of Ketamine
Myers, M. (2023) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2023-15485
MDMA-Assisted Therapy for Treatment of PTSD and Beyond
(2023) · Frontiers research topics · doi:10.3389/978-2-8325-3023-8
The Effectiveness of Drug Treatment for Depressive Symptoms
Xu, X. (2023) · Journal of Education Humanities and Social Sciences · doi:10.54097/ehss.v22i.13058
Zuo, M., Li, Y., Williams, J. P., Li, Y., Sun, L., Wang, R., Ren, G., Xu, Q., & An, J. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4797253
Stahl, S. M. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009464772.048
EPIDEMIOLOGIA DA DEPRESSÃO, FISIOPATOLOGIA E ANÁLISE DO USO DA ESKETAMINA: UMA REVISÃO INTEGRATIVA
GENOVESE, E. B., MOREIRA, G. W., Rocha, I. N. D. S., DOBLER, J., & TERRA, R. M. (2024) · doi:10.59290/978-65-6029-117-1.8
Research Progress of Esketamine in Improving Perioperative Depression and Sleep Quality
高, 永. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1472116
Assessing the Efficacy of Methods for Treatment-Resistant Depression: A Review
Crisan, Z. (2024) · Journal of Student Research · doi:10.47611/jsrhs.v13i1.6275
Chapter 22. Ketamine and Other Investigational Agents
(2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379620.lg22
Chapter 32. Combination Pharmacological Strategies for Antidepressant Treatment
(2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379620.lg32
Chapter 33. Management of Treatment-Resistant Depression
(2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379620.lg33
Effects of Ketamine and Esketamine on Cognitive Functions in Treatment-Resistant Depression
Mutlu, M., Öven, Ç., Kurt, B. S., & SUNAY, E. (2025) · Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry · doi:10.18863/pgy.1524106
Anhedonia: a unifying symptom and a transdiagnostic therapeutic target
Rosso, G., Pesci, N. R., PERACCHIA, S., Garrone, C., Salvo, G. D., & Maina, G. (2025) · Minerva Psychiatry · doi:10.23736/s2724-6612.24.02572-7
Back, M. S., Santiago, P. R. B., & Pellin, G. M. (2025) · Revista Contemporânea · doi:10.56083/rcv5n2-072
Increased Use and State-Level Variation of Esketamine Prescriptions Among Medicare Patients
Cavanah, L. R. (2025) · American Journal of Psychiatry Residents Journal · doi:10.1176/appi.ajp-rj.2025.200302
Stereotactic radiosurgery for treatment resistant depression: Systematic review
Vanleuven, J., Hori, Y. S., Osama, T. A., Harary, P. M., Lui, A., Persad, A. R. L., Tayag, A. T., Emrich, S. C., Ustrzynski, L., Purger, D. A., et al. (2025) · World Neurosurgery X · doi:10.1016/j.wnsx.2025.100451
Uso de Ketamina Intranasal en Depresión Resistente: Evidencia Clínica y Perspectivas Terapéuticas
Knupflemacher, D. S., Rojas, J. M. M., Hernández, L. F. P., Sillas, V. A. A., & Hernández, V. D. A. H. (2025) · Revista Científica de Salud y Desarrollo Humano · doi:10.61368/r.s.d.h.v6i2.617
Skowron, C. S., Miłkowska, U., Piech, G. M., Lis, I., & Kurzyna, P. F. (2025) · Biuletyn Głównej Biblioteki Lekarskiej · doi:10.2478/bgbl-2025-0011
Szawarnoga, D., & Sołtys, W. (2025) · Polish Annals of Medicine · doi:10.29089/paom/203684
Eficácia da esketamina intranasal na depressão resistente: uma revisão de escopo
Guerra, G. M., Galvão, L. D. F. B., de Siqueira, M. C. C., do Rêgo, M. P. P., Florentino, R. B., de Oliveira, P. G. G., & Silva, H. R. D. S. E. (2025) · Revista Neurociências · doi:10.34024/rnc.2025.v33.19845
Metadata
- Authors
- Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., Ravindran, A., Gaillard, R., Ameele, H. V. D., Preskorn, S., Manji, H., Hough, D., Drevets, W. C., & Singh, J. B.
- Affiliations
- Janssen Research and Development, Department of Neuroscience, Titusville, New Jersey
- The University of Texas Southwestern Medical Center (US)
- Janssen Research and Development, Clinical Biostatistics, Titusville, New Jersey
- University of Ottawa (CA)
- Clinical Trials Network and Institute, Massachusetts General Hospital, Boston, Massachusetts
- Medical Research Network (US)
- University of Toronto (CA)
- Centre Hospitalier Sainte Anne, Service Hospitalo-Universitaire, Paris, France
- AZ Sint-Jan (BE)
- University of Kansas (US)
- Janssen Research and Development, Department of Neuroscience, San Diego, California
- Corresponding author
- Fedgchin, Maggie
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-07-10
- Volume
- 22
- Issue
- 10
- Pages
- 616-630
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC6822141
- OpenAlex
- W2961020354
- Semantic Scholar
- 3739b211f156e1c4836c25e44222f6497502cdd7
- Cited by
- 606
- References
- 32
- Citations by year
- 2026: 49 · 2025: 73 · 2024: 58 · 2023: 59 · 2022: 72 · 2021: 62 · 2020: 222 · 2019: 10
- FWCI
- 56.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- esketamine, nasal spray, treatment-resistant depression, antidepressant combination therapy, rapid-acting antidepressants, antidepressant non-response, depression remission, adverse events, dissociation, nausea
- MeSH terms
- Duloxetine Hydrochloride, Venlafaxine Hydrochloride, Administration, Intranasal, Administration, Oral, Adolescent, Adult, Antidepressive Agents, Delayed-Action Preparations, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Ketamine, Male, Middle Aged, Citalopram, Treatment Outcome, Sertraline, Young Adult, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.